Maksim Labkouski Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson ( JNJ )/Ambrx, Merck ( MRK )/Harpoon, GSK ( GSK )/Aiolos and Novartis( NVS )/Calypso in early January. Other major deals announced before the end of the quarter included Gilead (.
Back to Health Page
